Does Warfarin or Rivaroxaban at Low Anticoagulation Intensity Provide a Survival Benefit to Asian Patients With Atrial Fibrillation?

Front Cardiovasc Med · 2021 · PMC8655790 · PMID 34901228

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a clear trendno p-value reported

Anticoagulant-Untreated Groups for Mortality There was a clear trend showing that NVAF patients using rivaroxaban (≤ 10, 15, 20 mg) had a significantly lower incidence of mortality than patients without anticoagulant treatment (log-rank test p < 0.001) ( Figure 3 ).

also in 19,460 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.